Polyspecificity - An emerging trend in the development of clinical antibodies-Reference-Cited by-同舟云学术

Polyspecificity - An emerging trend in the development of clinical antibodies

Published:2023-03 Issue: Volume:155 Page:175-183
ISSN:0161-5890
Container-title:Molecular Immunology
language:en
Short-container-title:Molecular Immunology

Author:

Sandeep ,Shinde Suraj H.,Pande Abhay H.

Publisher

Elsevier BV

Subject

Molecular Biology,Immunology

Reference71 articles.

1. Designing a new bispecific tandem single-chain variable fragment antibody against tumor necrosis factor-α and interleukin-23 using in silico studies for the treatment of rheumatoid arthritis;Barkhordari;J. Mol. Model.,2020

2. Barrett R.R. et al., (2014). Compound targeting IL-23a and TNF-alpha and uses thereof (U.S. Patent no. US 10,059,763 B2). U.S. Patent and Trademark Office.

3. Combination therapy in combating cancer;Bayat Mokhtari;Oncotarget,2017

4. AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease;Bhol;Inflamm. Bowel Dis.,2013

5. Cai Yumin. (2018). Bispecific antibody (CN108640997).

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism-Driven Design of Multispecific Antibodies for Targeted Disease Treatment;Annual Review of Chemical and Biomolecular Engineering;2024-07-24

2. Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1;mAbs;2024-06-07

3. Polyvalency: an emerging trend in the development of clinical antibodies;Drug Discovery Today;2024-01

4. Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics;Immunology;2023-12-23

5. Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status;Medical Oncology;2023-12-21